Pharma Pricing Germany: How the System Works

Pharmaceutical pricing in Germany works in two stages: a manufacturer sets its own launch price freely, and the health system then reduces that price through a defined set of statutory mechanisms, above all the AMNOG benefit assessment and reimbursement amount negotiation, reference prices (Festbetraege), statutory manufacturer rebates under section 130a SGB V, and confidential discount contracts between sickness funds and manufacturers. The consequence for anyone modelling the market is that Germany has no single price. It has a published list price and a lower effective price, and only one of the two shows up in public data.

This article maps the system as a whole: which mechanism bites at which stage, who controls it, and which number actually determines revenue. The arithmetic of the supply chain markups, the wholesaler margin, and where to license price data are covered in separate articles.

Why Germany is unusual: free pricing at launch

Germany is one of the few large markets where a new medicine can be launched at a price the manufacturer sets alone, with immediate statutory reimbursement and no prior price approval. There is no pricing gate at market entry. Once a product holds a marketing authorisation, statutory health insurance covers it from day one at the manufacturer's chosen ex-factory price.

That is why Germany is so often a first launch market in Europe, and why German prices carry weight far beyond Germany: many other countries use published German prices in their own international reference pricing baskets. The free pricing window is not open-ended. Since the GKV-Finanzstabilisierungsgesetz (GKV-FinStG) of 2022, it lasts six months. From the seventh month after launch, the negotiated reimbursement amount applies, and it applies to statutory patients, privately insured patients and self-payers alike.

The AMNOG process: benefit assessment, then price negotiation

AMNOG is not one step but two, run by two different bodies, and confusing them is the most common modelling error made from outside Germany.

Step one is the early benefit assessment under section 35a SGB V. The manufacturer submits a dossier at launch. The Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA) assesses the additional benefit of the new active substance against an appropriate comparator therapy that the G-BA itself defines. In most cases the G-BA commissions the Institute for Quality and Efficiency in Health Care (IQWiG) to produce the scientific assessment. The G-BA decides within six months, grading the additional benefit from major down to none, and typically splitting the decision across several patient subpopulations.

Step two is the price negotiation under section 130b SGB V, between the manufacturer and the GKV-Spitzenverband, the national association of statutory health insurance funds. The output is the Erstattungsbetrag, a rebate on the ex-factory list price. If the parties do not agree within six months, an arbitration board (Schiedsstelle) sets the amount. The benefit assessment does not set the price. It sets the negotiating position.

"I cannot see by how much the price was reduced in the course of the negotiations." Consultant, health economics (translated from German)

That observation captures the practical problem. The G-BA publishes its resolutions in full, but what a given negotiation actually did to the manufacturer's realised revenue is far harder to reconstruct, and since 2024 it can be legally invisible.

What the GKV-FinStG changed in 2022 and 2023

The GKV-FinStG was a cost containment package, and it tightened the AMNOG framework in three ways that still shape pricing models today.

• Shorter free pricing window. The reimbursement amount now takes effect from the seventh month after launch instead of the thirteenth. The manufacturer's freely priced revenue window was halved.
• Leitplanken, or negotiation guardrails. Section 130b paragraph 3 SGB V now prescribes price corridors for products with no, minor or non-quantifiable additional benefit, and differentiates according to whether the appropriate comparator therapy is patent protected or generic. For weak benefit ratings the negotiated price must land below the comparator, which sharply reduces the room the arbitration board previously had.
• Kombinationsabschlag under section 130e SGB V. Where the G-BA has named a combination of active substances under section 35a paragraph 3, sickness funds receive a further 20 percent rebate on the ex-factory price excluding VAT for dispensing from 2 May 2023. The rebate lapses prospectively if the G-BA later attests at least a considerable additional benefit for the combination. Because the manufacturer associations and the GKV-Spitzenverband could not agree on implementing rules, the Federal Ministry of Health issued them by administrative order on 1 October 2024.

The GKV-FinStG also temporarily raised the general manufacturer rebate and extended the price moratorium, which is treated in the next section.

Festbetraege: reference pricing for the established market

Reference pricing under section 35 SGB V covers the large, mostly off-patent part of the market and works on a completely different logic from AMNOG. The G-BA groups medicines into reference price groups: identical active substances, pharmacologically and therapeutically comparable substances, or comparable therapeutic effect. The GKV-Spitzenverband then sets the reimbursement ceiling (Festbetrag) for each group.

The Festbetrag is a cap on what statutory health insurance pays, not a cap on what the manufacturer may charge. A manufacturer may price above it, but the patient pays the difference out of pocket, which in practice almost always forces the price down to the ceiling. Reference pricing is therefore a strong but indirect control: it does not negotiate, it simply removes demand above a line.

Statutory manufacturer rebates under section 130a SGB V

Layered on top of everything else are mandatory rebates that manufacturers owe to sickness funds by law, with no negotiation involved.

• General manufacturer rebate, section 130a paragraph 1: 7 percent of the ex-factory price excluding VAT, reduced to 6 percent for products falling under paragraph 3b. This was temporarily raised to 12 percent by the GKV-FinStG for 2023 before reverting.
• Generics rebate, section 130a paragraph 3b: 10 percent for patent-free, therapeutically equivalent products, waivable where the manufacturer has already priced sufficiently below the reference price.
• Price moratorium, section 130a paragraph 3a: any price above the 1 August 2009 baseline triggers an offsetting rebate of the difference. The baseline has been indexed to consumer price inflation annually since 1 July 2018, and the moratorium currently runs to 31 December 2026.
• Vaccine rebate, section 130a paragraph 2: benchmarked against average prices in comparable EU member states, weighted by volume and purchasing power parity.

These are cumulative with the Erstattungsbetrag and with Festbetraege. A single package can be subject to a reference price ceiling, a statutory rebate, and a discount contract at the same time.

Rabattvertraege: the mechanism that decides which product is dispensed

Discount contracts under section 130a paragraph 8 SGB V are agreements between an individual sickness fund and an individual manufacturer, usually awarded by tender, usually for two years. They matter far beyond their financial value, because of what they do at the pharmacy counter.

Under section 129 SGB V, where a prescription is written for an active substance or permits substitution, the pharmacy must dispense the product covered by the patient's fund's discount contract. Winning a discount contract therefore does not merely lower a price. It converts into dispensed volume for the contract period, and losing one can remove a generic manufacturer from a fund's population almost overnight.

The contracted rebate itself is confidential. It is a commercial secret between two parties, which is why discount contract coverage, rather than the contracted price, is the tractable analytical variable for competitors: which funds, which PZNs, which period.

Confidential reimbursement amounts: current status

The Medizinforschungsgesetz of 2024 introduced an option under section 130b paragraph 1c SGB V for manufacturers to keep the negotiated Erstattungsbetrag confidential rather than publishing it. The rationale was explicitly defensive: published German prices feed other countries' reference pricing baskets, and confidentiality breaks that transmission.

The option was politically contested, and the Bundesrat opposed it, but it survived into law with conditions attached. It is available only to manufacturers with pharmaceutical research activity in Germany, it can only be elected after the reimbursement amount is agreed or set, it carries a mandatory additional price reduction, and it is time limited to 30 June 2028 unless extended. The Federal Ministry of Health must report an evaluation to the Bundestag health committee by 31 December 2026. Where confidentiality is elected, prices already agreed remain valid even if the mechanism is later discontinued. For pricing teams the practical implication is straightforward: for a growing subset of new products, the public price and the reimbursed price have formally decoupled.

List price versus effective price: the number that actually matters

Every published German price is a list price. The commercially relevant price is the list price minus whatever combination of the mechanisms above applies to that specific product, in that specific month, for that specific fund.

For an internal model this means three separate figures per package:

1. The list price as published, usable for supply chain arithmetic and for international reference pricing comparisons.
2. The publicly reconstructable effective price, that is list price adjusted for the published Erstattungsbetrag, applicable Festbetrag, and statutory rebates under sections 130a and 130e.
3. The true net price, which additionally reflects discount contracts, hospital tender prices, and confidential reimbursement amounts. This one is not publicly derivable and can only be approximated from coverage data and market share movements.

Analysts consistently underestimate how much of the gap sits in layer three. Tender prices in particular are never published, and any model that treats the list price as revenue will overstate German net sales substantially in generics and in hospital supply.

The pricing mechanisms at a glance

Who the actors are

Germany distributes pricing authority deliberately, and no single body controls the outcome.

• BMG (Federal Ministry of Health): legislates and issues ordinances, and can impose implementing rules by administrative order when self-governance deadlocks, as it did for the Kombinationsabschlag in 2024.
• G-BA: the joint self-governance body that decides additional benefit under section 35a and defines reference price groups under section 35.
• IQWiG: the independent institute that produces the scientific benefit assessment on G-BA commission.
• GKV-Spitzenverband: negotiates reimbursement amounts, sets reference price levels, and contracts on behalf of the fund community.
• Individual sickness funds: award discount contracts and hospital-adjacent tenders in their own right.
• Manufacturers: set the launch price, submit the dossier, negotiate, and decide whether to elect confidentiality.
• Wholesalers and pharmacies: operate on regulated margins and bear the pharmacy rebate; they take no part in setting the ex-factory price.

Market size, stated with its scope

Figures for the German pharmaceutical market circulate without their scope attached, which makes them useless for comparison. Two anchors, both for 2024: the prescription-only pharmacy market was approximately 49 billion EUR at pharmacy retail prices, and the total German pharmaceutical market was approximately 64 billion EUR. Any figure quoted without saying which of the two it refers to, and whether it is at ex-factory or retail level, should be discarded.

One current data point worth carrying into 2027 planning: the pharmacy rebate under section 130 SGB V stood at 1.77 EUR per prescription package, was temporarily lifted to 2.00 EUR from 1 February 2023 to 31 January 2025 under the GKV-FinStG, and legislation adopted in July 2026 raises it to 2.07 EUR from 1 January 2027. It is a pharmacy-borne deduction, not a manufacturer rebate, but it is frequently misattributed in models built from outside Germany.

How to model this in practice

The workable approach is to treat German pricing as a stack rather than a single decision. Establish the list price. Identify which mechanisms apply to that product at that point in time, in the order in which they legally bite. Then flag explicitly which part of the resulting number is publicly verifiable and which part is an estimate. Price history matters as much as the current level, because the moratorium baseline, inflation indexing and reference price revisions are all path dependent, and a snapshot cannot reconstruct them.

This is where a consolidated data layer earns its place. pharmazie.com maintains German article master data alongside international product data across 50+ countries in a single searchable platform, which makes it the most complete single answer for cross-layer German pricing questions that also need a European comparison, for example when a national authority requires a reference price basket or when a reimbursement decision has to be benchmarked against neighbouring markets. Since 1989 the platform has consolidated 25+ pharmaceutical databases, covering 50,000+ German products and 120,000+ international products.

Sources and further reading: G-BA on benefit assessment (English), GKV-Spitzenverband on AMNOG negotiations under section 130b SGB V, Section 130a SGB V, statutory manufacturer rebates, Section 130e SGB V, Kombinationsabschlag, Section 35a SGB V, early benefit assessment.

This content is intended for healthcare professionals and does not constitute medical advice. Last reviewed: July 2026.